What are the side effects of cyclophosphamide?

Cyclophosphamide Side Effects

Cyclophosphamide causes serious dose-dependent toxicities including bone marrow suppression, hemorrhagic cystitis, cardiotoxicity, infections, gonadal failure, and secondary malignancies that require aggressive prophylaxis and monitoring. 1, 2

Hematologic and Infectious Complications

Myelosuppression is universal and potentially life-threatening:

• Bone marrow toxicity manifests as leukopenia, neutropenia, thrombocytopenia, and anemia, with nadirs typically occurring in weeks 1-2 of treatment 2
• Pancytopenia and bone marrow failure can occur, particularly with high doses or concurrent chemotherapy/radiation 1, 2
• Severe immunosuppression leads to serious and sometimes fatal infections including sepsis and septic shock 2
• Infection rates reach 60-72% in treated patients, with documented bacterial, viral, and fungal infections 1
• Pneumocystis jirovecii pneumonia (PCP) prophylaxis with trimethoprim-sulfamethoxazole is mandatory for all patients on cyclophosphamide 3, 4
• Neutropenic fever requires immediate broad-spectrum antibiotics 1, 2

Urologic Toxicity

Hemorrhagic cystitis is a hallmark toxicity requiring aggressive prevention:

• Occurs in up to 6% of patients without protective measures 1, 3
• Acrolein (toxic metabolite) causes direct bladder injury, ranging from hematuria to severe hemorrhagic cystitis, pyelitis, and ureteritis 2, 5
• Long-term urotoxicity includes bladder ulceration, necrosis, fibrosis, contracture, and secondary bladder cancer 2
• Mesna (2-mercaptoethanesulfonate sodium) is mandatory for all IV pulse cyclophosphamide to prevent hemorrhagic cystitis 3, 4
• Aggressive hydration with forced diuresis and frequent bladder emptying reduces toxicity frequency and severity 1, 4, 2
• Urinary sediment should be monitored regularly for erythrocytes and signs of toxicity throughout treatment and follow-up 1, 2

Cardiovascular Toxicity

Cardiac complications are dose-related and potentially fatal:

• Myocarditis, myopericarditis, pericardial effusion (including cardiac tamponade), and congestive heart failure have been reported 1, 2
• Supraventricular arrhythmias (atrial fibrillation/flutter) and ventricular arrhythmias including severe QT prolongation occur 2
• Risk increases with high doses (>150 mg/kg), advanced age, previous cardiac radiation, or concurrent cardiotoxic agents 1, 2
• Pathogenic mechanisms involve direct vascular endothelial injury, toxic metabolite leakage, interstitial hemorrhage, edema, and intracapillary microemboli formation 1
• Estimated incidence of cyclophosphamide-myocarditis is 5% in children receiving doses >150 mg/kg 1

Gonadal Toxicity and Fertility

Reproductive toxicity is age- and dose-dependent:

• Amenorrhea occurs in 20-85% of menstruating women, with risk increasing with age and cumulative dose 1, 3, 2
• Azoospermia and gonadal failure occur in men 1, 5
• Fertility preservation counseling is mandatory before initiating therapy, especially in younger patients 3, 4
• The Euro-Lupus regimen (total dose 3 grams) carries lower infertility risk than oral or NIH regimens 3
• Limiting cumulative dose to <10 g is recommended for patients desiring fertility preservation 4

Malignancy Risk

Secondary malignancies represent serious long-term toxicity:

• Increased risk of leukemia, bladder cancer, lymphomas, and other malignancies 1, 2, 5
• Risk increases with cumulative cyclophosphamide exposure 4, 6
• Limiting total cumulative dose to <25 g (maximum 36 g) reduces secondary malignancy risk 4
• Malignancies develop after median 4.7 years (range 0.25-22.25 years) 6
• Lifelong urinalysis screening for bladder cancer is required 4
• Age-appropriate cancer screening with enhanced surveillance for bladder cancer, myeloid leukemia, and skin cancer is recommended 4

Gastrointestinal and Other Common Toxicities

Multiple organ systems are affected:

• Nausea, vomiting, diarrhea, abdominal pain, stomatitis, mucositis, and anorexia are common 1, 2
• Hair loss (alopecia) occurs frequently and is reversible 1, 2, 7
• Hepatotoxicity can occur, requiring liver function monitoring 1, 3
• Pulmonary toxicity includes interstitial pneumonitis and pulmonary fibrosis 1, 2
• Toxic epidermal necrolysis is a rare but serious dermatologic complication 1
• Dizziness, blurred vision, and visual impairment may affect ability to drive or operate machinery 2

Monitoring and Management Requirements

Intensive surveillance is essential:

• Complete blood counts must be monitored to detect acute leukopenia or gradual decline, with dose adjustments or discontinuation as necessary 3, 4, 2
• Cyclophosphamide should not be administered when neutrophils ≤1,500/mm³ and platelets <50,000/mm³ 2
• Temperature monitoring is critical with immediate reporting of fever 2
• Peripheral blood cell counts typically normalize after approximately 20 days 2
• G-CSF may be administered to reduce neutropenia complications, with primary and secondary prophylaxis considered in high-risk patients 2